study Archives | PharmaShots

Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

May 17, 2019May 17, 2019Tuba Khan

Shots: The P-II EMPOWER CSCC-1 study results involve assessing of Libtayo (cemiplimab-rwlc) in patients with LA & metastatic CSCC and will be presented [...]

Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

May 15, 2019May 16, 2019Tuba Khan

Shots: The P-III LIBERTY 1 study results involves assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg)/relugolix (40mg) as monothx. + [...]

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED Study to Prevent Sudden Cardiac Death

May 13, 2019May 15, 2019Tuba Khan

Shots: The UNTOUCHED study involves assessing Emblem Subcutaneous Implantable Defibrillator (S-ICD) system in 1,116 patients with a left ventricular ejection fraction (LVEF) ≤35% [...]

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

May 10, 2019May 15, 2019Tuba Khan

Shots: The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- [...]

Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes

May 9, 2019May 10, 2019Tuba Khan

Shots: The SMILE study involves assessing of MiniMed 640G system with SmartGuard technology vs insulin pump therapy without continuous glucose monitoring (CGM) in [...]

AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

May 8, 2019May 10, 2019Tuba Khan

Shots: The P-II DESTINY-Breast01 study involves assessing of Trastuzumab Deruxtecan (DS-8201) in 253 patients with HER2+ unresectable and/or m-breast cancer prior treated with [...]

study

Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED Study to Prevent Sudden Cardiac Death

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes

AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma